bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for the three months ended March 31, 2015.
* At constant exchange rates and scope of consolidation
Alexandre Mérieux, Chief Executive Officer, said: "In the first quarter of 2015, bioMérieux once again demonstrated the solidity of its growth model. Led by all the applications and the robust momentum in the Americas, organic growth in sales ended the period at 8.7%, exceeding our annual target. In particular, BioFire Diagnostics delivered 93% organic growth, attesting to FilmArray®'s market success in North America and the medical value of the syndromic diagnosis of infectious diseases. In addition, we stepped up our sales performance in clinical microbiology, where we are the global market leader. Backed by a vigorous start to the year, we are confirming our objective of organic growth in sales in 2015, while actively pursuing the operating projects designed to drive sustainable and profitable growth in our business."
Download the Full Press Release: